RSC – RSC Med. Chem. latest articles- Salicylamide derivatives as potent HBV inhibitors: insights into structure–activity relationships May 7, 2025RSC Med. Chem., 2025, Advance ArticleDOI: 10.1039/D5MD00222B, Research ArticleJingwen Huo, Jizhen Xiao, Yushi Zhang, Xinhui Qiu, Xuechen Huang, Ge Wang, Jianhao Wang, Kuancheng Liu, Jimin XuA series of salicylamide derivatives have been designed, synthesized, and evaluated as potent anti-HBV agents, with preliminary mechanistic insights.To cite this article before page numbers are assigned, use the DOI […]Jingwen Huo
- Revisiting the role of steroidal therapeutics in the 21st century: an update on FDA approved steroidal drugs (2000–2024) May 7, 2025RSC Med. Chem., 2025, Advance ArticleDOI: 10.1039/D5MD00027K, Review ArticleRanjit Singh, Ranju BansalThe present review article provides information about the steroidal drugs approved by the US FDA during the years 2000–2024 and repurposing of steroidal drugs for various disorders in the 21st century.To cite this article before page numbers are assigned, use the DOI form of […]Ranjit Singh
- Design, synthesis and biological evaluation of novel β-caryophyllene derivatives as potential anti-cancer agents through the ROS-mediated apoptosis pathway May 7, 2025RSC Med. Chem., 2025, Advance ArticleDOI: 10.1039/D4MD00951G, Research ArticleZhiwei Wang, Yang Chen, Anjie Huang, Hui Wen, Yetian Wu, Xingjun Xu, Zhongjing Qiao, Liangyu Chen, Yaopeng Zhao, Xinmiao LiangThe β-CP derivative AC-7 exerted potent anti-tumor activity both in vitro and in vivo, suggesting that AC-7 is a promising candidate for anti-CRC therapy, acting through the ROS-mediated […]Zhiwei Wang
- Design, synthesis and evaluation of Pyrrolobenzodiazepine (PBD)-based PROTAC conjugates for the selective degradation of the NF-κB RelA/p65 subunit May 7, 2025RSC Med. Chem., 2025, Accepted ManuscriptDOI: 10.1039/D5MD00316D, Research Article Open Access   This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.Peiqin Jin, Md. Mahbub Hasan, Andrea G.S. Pepper, Simon Mitchell, Khondaker Miraz Rahman, Chris PepperNF-κB signalling is frequently dysregulated in human cancers making it an attractive therapeutic target. Despite concerted efforts to […]Peiqin Jin
- Improved Anti-Breast Cancer Activity Through Structural Modification of Fused Pyran Derivatives and Mechanistic Investigations May 6, 2025RSC Med. Chem., 2025, Accepted ManuscriptDOI: 10.1039/D5MD00161G, Research Article Open Access   This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.K. Fabitha, Anoop Kallingal, Natalia Maciejewska, Hiba Haneefa P.T, Varun Thachan Kundil, Majed Alharbi, Janardhan BanothuNovel fused pyran derivatives were synthesized and evaluated for anticancer activity against MCF7 (breast), A549 (lung), and […]K. Fabitha
- 2D and 3D Anticancer Activity of Diiron Bis-Cyclopentadienyl Complexes Incorporating Flurbiprofen and Chlorambucil May 5, 2025RSC Med. Chem., 2025, Accepted ManuscriptDOI: 10.1039/D4MD01011F, Research ArticleLorenzo Biancalana, Michele De Franco, Valentina Gandin, Fabio MarchettiThe new diiron complex [Fe2Cp2(CO){Ph2P(4-C6H4CO2H)}(μ-CO){μ-CNMe(Cy)}]CF3SO3, [2]CF3SO3 (Cp = η5-C5H5, Cy = C6H11), was synthesized with a yield of 90 % from a tricarbonyl precursor and 4-(diphenylphosphanyl)benzoic acid. The carboxylic acid...The content of this RSS Feed (c) The Royal Society […]Lorenzo Biancalana
- Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay May 5, 2025RSC Med. Chem., 2025, Advance ArticleDOI: 10.1039/D4MD01008F, Research ArticleSamuel Jacob Bunu, Haiyan Cai, Zhaoyin Zhou, Yanlei Zhang, Yue Lai, Guanli Wang, Dongliang Song, Chengkun Wu, Hang Zheng, Zhijian Xu, Jumei Shi, Weiliang ZhuThe study identified novel molecules as TRIP13 inhibitors with good anti-multiple myeloma activity, which could be developed into TRIP13-based multi-target drugs.To cite this […]Samuel Jacob Bunu
- Niclosamide: CRL4AMBRA1 mediated degradation of cyclin D1 following mitochondrial membrane depolarization May 5, 2025RSC Med. Chem., 2025, Advance ArticleDOI: 10.1039/D5MD00054H, Research Article Open Access   This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.Seemon Coomar, Jessica A. Gasser, Mikołaj Słabicki, Katherine A. Donovan, Eric S. Fischer, Benjamin L. Ebert, Dennis Gillingham, Nicolas H. ThomäNiclosamide, an FDA-approved anthelmintic drug, known to uncouple the mitochondria induces cyclin […]Seemon Coomar
- Macrocyclic RGD-Peptides with High Selectivity for αvβ3 Integrin in Cancer Imaging and Therapy May 2, 2025RSC Med. Chem., 2025, Accepted ManuscriptDOI: 10.1039/D5MD00280J, Research ArticleXiaozhong Cheng, Chen Li, haofei hong, Zhifang Zhou, Zhimeng WuIntegrins, particularly the αvβ3 subtype, are critical receptors involved in cell adhesion, migration, and signaling, playing a significant role in tumor progression and metastasis. Despite extensive research into integrin-targeted therapies,...The content of this RSS Feed (c) The Royal […]Xiaozhong Cheng
- A context-based Matched Molecular Pair Analysis identifies structural transformations that reduce CYP1A2 Inhibition. May 1, 2025RSC Med. Chem., 2025, Accepted ManuscriptDOI: 10.1039/D4MD01012D, Research ArticleJanvi Raut, Vaibhav Anil DixitCytochrome P450 1A2 (CYP1A2) metabolizes ~10-15 % of FDA-approved drugs. Available Quantitative Structure-Activity Relationship (QSAR) and machine learning methods offer little design insights to reduce CYP1A2 inhibition. We performed Matched...The content of this RSS Feed (c) The Royal Society of ChemistryJanvi Raut
- Salicylamide derivatives as potent HBV inhibitors: insights into structure–activity relationships May 7, 2025
